Holen Sie sich die Stockscreener-App
4.88
3.75%
-0.19
Schlusskurs vom Vortag:
$5.07
Offen:
$5.15
24-Stunden-Volumen:
301.62K
Relative Volume:
0.82
Marktkapitalisierung:
$161.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-62.31M
KGV:
-1.9963
EPS:
-2.4445
Netto-Cashflow:
-
1W Leistung:
-15.86%
1M Leistung:
-22.29%
6M Leistung:
-56.39%
1J Leistung:
-70.12%
1-Tages-Spanne:
$4.85
$5.16
1-Wochen-Bereich:
$4.78
$6.06
52-Wochen-Spanne:
$4.78
$19.50
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.88 | 161.42M | 0 | -62.31M | 0 | -2.4445 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo Therapeutics (NASDAQ:LXEO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Barclays PLC Acquires 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus Target Price from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Lexeo stock plunges to 52-week low, hits $5.75 amid market challenges - Investing.com Nigeria
How to Take Advantage of moves in (LXEO) - Stock Traders Daily
Jane Street Group LLC Buys 8,918 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexeo Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Increases Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Geode Capital Management LLC Acquires 256,635 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Barclays PLC Buys 31,057 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Raised by State Street Corp - Defense World
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
BNP Paribas Financial Markets Increases Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Charles Schwab Investment Management Inc. Buys 33,013 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Lexeo Therapeutics appoints new CFO amid growth - Investing.com
Lexeo Therapeutics Appoints Dr. Kyle Rasbach as CFO - TipRanks
Lexeo Therapeutics Names Kyle Rasbach Chief Financial Officer - MarketWatch
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - The Manila Times
Lexeo Therapeutics Appoints Investment Veteran & Life Sciences Expert Dr. Rasbach as New CFO - StockTitan
Lexeo Therapeutics, Inc. Appoints Kyle Rasbach as Chief Financial Officer - Marketscreener.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock's potential and pitfalls - Investing.com
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts By Investing.com - Investing.com Nigeria
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for catalysts - Investing.com India
Frazier Life Sciences Management L.P. Invests $11.31 Million in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Point72 Asset Management L.P. Makes New $3.35 Million Investment in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Janus Henderson Group PLC Purchases 599,203 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
RA Capital Management L.P. Reduces Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
LXEOLexeo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Verition Fund Management LLC Boosts Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Eventide Asset Management LLC Has $16.78 Million Holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Sold by Braidwell LP - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Insider Spends US$105k Buying More Shares In Lexeo Therapeutics - Simply Wall St
Paula H. Cholmondeley Bought 96% More Shares In Lexeo Therapeutics - Yahoo Finance
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Analysts - MarketBeat
Insider Buying: Paula Cholmondeley Acquires 15,000 Shares of Lex - GuruFocus.com
Can Lexeo's HEROIC-PKP2 Data Reignite Stock Rally? - RTTNews
Lexeo stock hits 52-week low at $5.8 amid market challenges - Investing.com India
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - Yahoo Finance
(LXEO) Trading Advice - Stock Traders Daily
FY2024 EPS Forecast for Lexeo Therapeutics Cut by Analyst - MarketBeat
FY2024 Earnings Estimate for LXEO Issued By Leerink Partnrs - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Dec 10 '24 |
Sale |
8.20 |
2,500 |
20,491 |
120,695 |
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):